ロード中...
Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience
Immune checkpoint inhibitors (ICIs) like cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) and programmed death cell protein 1 (anti-PD1) have revolutionized cancer treatment. As ICI use becomes widespread, more immune-related adverse events (irAE's) are being reported. Our aim was to in...
保存先:
| 出版年: | Medicine (Baltimore) |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Health
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6799752/ https://ncbi.nlm.nih.gov/pubmed/31593084 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000017348 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|